A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
ABSTRACT Bones have been suggested to be a target for glucagon‐like peptide ‐1 (GLP‐1); however, studies of the effects on human bones so far have given diverging results. We hypothesized that GLP‐1, together with glucagon‐like peptide‐2 and glucose‐dependent insulinotropic polypeptide, plays a role...
Main Authors: | Anne Nissen, Simone Marstrand, Kirsa Skov‐Jeppesen, Lasse Bremholm, Mads Hornum, Ulrik B Andersen, Jens Juul Holst, Mette Marie Rosenkilde, Bolette Hartmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-10-01
|
Series: | JBMR Plus |
Subjects: | |
Online Access: | https://doi.org/10.1002/jbm4.10209 |
Similar Items
-
The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
by: Sity Aishah Mansur, et al.
Published: (2019-02-01) -
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01) -
Effects of calcitonin nasal spray on serum bone resorptive marker CTX and other laboratory findings in osteopenic menopausal women: a clinical trial
by: Bayat N, et al.
Published: (2012-07-01) -
Commercial Laboratory Reproducibility of Serum CTX in Clinical Practice
by: Sahar M Hindi, et al.
Published: (2019-10-01) -
Addendum 2: Forum for Injection Technique, India
by: Sanjay Kalra, et al.
Published: (2014-01-01)